This company has been acquired
Y-mAbs Therapeutics (YMAB) Stock Overview
A commercial-stage biopharmaceutical company, focuses on the development and commercialization of radioimmunotherapy and antibody based therapeutic products for the treatment of cancer. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
YMAB Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Y-mAbs Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$8.61 |
| 52 Week High | US$16.11 |
| 52 Week Low | US$3.55 |
| Beta | 0.53 |
| 1 Month Change | 1.06% |
| 3 Month Change | 79.38% |
| 1 Year Change | -33.82% |
| 3 Year Change | -39.62% |
| 5 Year Change | -77.09% |
| Change since IPO | -64.13% |
Recent News & Updates
Recent updates
Y-mAbs Therapeutics: The Next Deal Showcases The Value And Challenges Of Biotech M&A
Aug 06Earnings Update: Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Just Reported Its First-Quarter Results And Analysts Are Updating Their Forecasts
May 16
Insufficient Growth At Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Hampers Share Price
Apr 29
DANYELZA And Radiopharmaceuticals Realignment Will Energize Global Opportunities
Strategic realignment into DANYELZA and Radiopharmaceuticals could enhance revenue growth and operational efficiency through focused business units.Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Just Reported And Analysts Have Been Cutting Their Estimates
Mar 07Y-mAbs Therapeutics: Finding Direction Through The Murk Of Clinical Trials
Jan 24Benign Growth For Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Underpins Stock's 26% Plummet
Jan 10We Think Y-mAbs Therapeutics (NASDAQ:YMAB) Can Afford To Drive Business Growth
Dec 10The Market Doesn't Like What It Sees From Y-mAbs Therapeutics, Inc.'s (NASDAQ:YMAB) Revenues Yet As Shares Tumble 26%
Nov 19Y-mAbs Therapeutics: Slow But Steady Prospect In Rare Cancers
Oct 21Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Held Back By Insufficient Growth Even After Shares Climb 33%
Sep 12Revisiting Y-mAbs After The Summer Oncology Meeting (Rating Upgrade)
Aug 12We're Not Worried About Y-mAbs Therapeutics' (NASDAQ:YMAB) Cash Burn
Jul 15Investors Don't See Light At End Of Y-mAbs Therapeutics, Inc.'s (NASDAQ:YMAB) Tunnel And Push Stock Down 29%
Jun 02Y-mAbs: There's A Ceiling Here Somewhere
May 09We're Not Worried About Y-mAbs Therapeutics' (NASDAQ:YMAB) Cash Burn
Mar 14Y-mAbs Therapeutics, Inc.'s (NASDAQ:YMAB) Shares Bounce 66% But Its Business Still Trails The Industry
Feb 17Y-mAbs Therapeutics: A Monoclonal Antibody Play
Jan 14We're Not Very Worried About Y-mAbs Therapeutics' (NASDAQ:YMAB) Cash Burn Rate
Nov 13Shareholder Returns
| YMAB | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 0.2% | -2.0% | -1.1% |
| 1Y | -33.8% | 22.9% | 14.7% |
Return vs Industry: YMAB underperformed the US Biotechs industry which returned -9.4% over the past year.
Return vs Market: YMAB underperformed the US Market which returned 18.5% over the past year.
Price Volatility
| YMAB volatility | |
|---|---|
| YMAB Average Weekly Movement | 29.9% |
| Biotechs Industry Average Movement | 11.2% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 16.5% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: YMAB's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: YMAB's weekly volatility has increased from 17% to 30% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 104 | Mike Rossi | www.ymabs.com |
Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of radioimmunotherapy and antibody based therapeutic products for the treatment of cancer. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow. The company also develops DANYELZA for the treatment of patients with second-line relapsed osteosarcoma and is in Phase II clinical study; GD2-SADA, which is in Phase I clinical trial for the treatment of GD2 positive solid tumors; and Omburtamab, an antibody for the treatment of central nervous system/leptomeningeal metastases from neuroblastoma.
Y-mAbs Therapeutics, Inc. Fundamentals Summary
| YMAB fundamental statistics | |
|---|---|
| Market cap | US$390.32m |
| Earnings (TTM) | -US$22.22m |
| Revenue (TTM) | US$85.39m |
Is YMAB overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| YMAB income statement (TTM) | |
|---|---|
| Revenue | US$85.39m |
| Cost of Revenue | US$15.80m |
| Gross Profit | US$69.58m |
| Other Expenses | US$91.81m |
| Earnings | -US$22.22m |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.49 |
| Gross Margin | 81.49% |
| Net Profit Margin | -26.03% |
| Debt/Equity Ratio | 0% |
How did YMAB perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/09/15 06:49 |
| End of Day Share Price | 2025/09/15 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Y-mAbs Therapeutics, Inc. is covered by 8 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Peter Lawson | Barclays |
| Thomas Shrader | BTIG |
| Etzer Darout | Guggenheim Securities, LLC |